青少年抑郁症患者性激素受体基因微卫星多态性与功能失调性认知的关系

目的探讨青春期首发的青少年抑郁症患者性激素受体基因微卫星多态性是否与功能失调性认知存在联系。方法采用聚合酶链式反应（PcR）结合毛细管电泳和基因扫描技术。检测青春期首发的青少年抑郁症患者雄激素受体（AR）、雌激素受体α（ERα）、雌激素受体β（ERβ）基因重复序列多态性的重复片段长度。应用《功能失调性态度问卷》（DAS）对青少年抑郁症患者进行评估，并把评估结果和微卫星多态片段长度进行相关性和对照性分析。结果1．女性患者ERβ基因微卫星多态性与DAS总分呈显著仉相关；2．对各位点等位基因分长短片段作组间比较。发现ERα短片段组DAS总分显著高于长片段组。男性患者不存在这种差异性。3．AR受体与功能失调性认知不存在这种联系。结论女性青少年ERα、ERβ受体基因微卫星多态可能与功能失调性认知存在联系，而男性青年抑郁症患者可能不存在这种联系。     

器械科(处)领导如何对医用耗材实施有效管理

医用耗材的有效管理对保证医疗质量具有重要意义,也是临床工程部门器械科(处)的主要任务之一.本文通过分析医用耗材特征,提出了医用耗材管理的基本目标和原则,并结合实践给出了构建管理基础及例外管理的具体措施,为器械科(处)领导实施耗材的有效管理提供参考.     

9岁女患儿的原发性气管雪旺细胞瘤（神经鞘瘤）

作者报道1例患原发性气管雪旺细胞瘤(神经鞘瘤)的9岁女患儿合并气道梗阻。CT扫描发现气管内多息肉样肿块,73%的管腔发生梗阻。行气管部分切除及吻合术。病检确诊为起源于雪旺细胞的良性神经源性肿瘤。9岁女患儿的原发性气管雪旺细胞瘤(神经鞘瘤)@Nio M. @Sano N. @Kotera     

某市区儿童肥胖现状及影响因素的现况调查

目的:了解重庆市区儿童肥胖的现状及危险因素,为家长、教育系统实施干预提供依据,以预防成年期相关疾病的发生。方法:随机抽取该地区3~16岁儿童1 867例,采用问卷方式收集资料进行现况调查,以BMI法为肥胖的诊断标准,采用国内推荐的BMI≥28.0 kg/m2将儿童分为肥胖组和正常对照组。结果:儿童肥胖的发生率为12.59%(男13.83%,女9.74%)。危险因素分析显示,有肥胖家族史、每日肉食摄入量、营养食品的添加、母乳喂养时间短、过早添加固体食物、看电视为主要危险因素,VitC是肥胖的保护因素。结论:该区儿童肥胖率明显高于历年水平,呈发展趋势,在儿童实施早期干预措施对预防青春期及成年期肥胖和其他相关疾病有重要的意义。     

1995～2004年广东省医院管理研究文献量的统计分析

引用中国生物医学光盘数据库(CBMdisc)收录全国及广东省十年间医院管理发表的文献量、全国10大城市医院管理的文献量排名和广东省内21个省市级医院发表医院管理文献量排名等进行统计分析,并且提出建议。     

体外电磁冲击波碎石术对输尿管结石疗效分析

探讨输尿管结石体外电磁冲击波碎石术效果，评价其应用价值。370例输尿管结石病人按结石部位、大小、结石停留时间分类，将各类结石疗效进行比较。输尿管结石碎石次数与结石大小相关（P〈0.05。不同部位同等大小结石碎石次数无显著差异。排石效果与结石大小不相关，而与病程长短相关（P〈0.05）。体外电磁冲击波碎石术是治疗输尿管结石首选方法，严格把握适应证可提高碎石疗效。     

Polymorphisms and circulating levels in the insulin-like growth factor system and risk of breast cancer: a systematic review.

We reviewed all English-language articles on associations among circulating levels of the insulin-like growth factors (IGF) and their binding proteins (IGFBP), polymorphisms in their genes, and breast cancer risk. In premenopausal women, five of eight IGF-I studies and four of six IGFBP-3 studies of circulating levels found that women in the highest quantile had more than twice the risk of developing breast cancer of those in the lowest, although in some this effect was only apparent at young ages. In postmenopausal women, however, there was no consistent effect. A simple sequence length polymorphism 1 kb 5' to IGF-I was examined in relation to circulating levels of IGF-I (12 studies) or breast cancer risk (4 studies), but there was no convincing evidence of any effect. For an A/C polymorphism 5' to IGFBP-3, all three studies were consistent with a modest effect on circulating levels, but no evidence of a direct effect on breast cancer risk was seen in the only relevant study. Variation within the reference range of IGF-I and IGFBP-3 may confer only modest increases in breast cancer risk, and any single polymorphism may only account for a small proportion of that variation. Nevertheless, population attributable fractions for high circulating levels of IGF-I and IGFBP-3 and for common genetic variants could be substantial. Further large studies, or combined analysis of data from existing studies, are needed to quantify these effects more precisely.     

Pivotal study of iodine-131-labeled chimeric tumor necrosis treatment radioimmunotherapy in patients with advanced lung cancer.

PURPOSE: Tumor necrosis treatment (TNT) uses degenerating tumor cells and necrotic regions of tumors as targets for radioimmunotherapy. Previous studies in animal tumor models and clinical trials have demonstrated that when linked to the therapeutic radionuclide iodine-131, recombinant chimeric TNT antibody ((131)I-chTNT) can deliver therapeutic doses to tumors regardless of the location or type of malignancy. Therapeutic efficacy and toxicity of (131)I-chTNT in advanced lung cancer patients were studied in this pivotal registration trial. PATIENTS AND METHODS: Patients with advanced lung cancer were treated with systemic or intratumoral injection of (131)I-chTNT in eight oncology centers in China. The objective response rate (ORR) was assessed as the primary end point. RESULTS: All 107 patients who were entered onto the study and completed therapy had experienced treatment failure after prior radiotherapy or chemotherapy a mean of three times. The results showed an ORR of 34.6% (complete response, 3.7%; partial response, 30.8%; no change, 55.1%; and progressive disease, 10.3%) in all patients and 33% in 97 non-small-cell lung cancer patients. A biodistribution study demonstrated excellent localization of the radioactivity in tumors in both systemically and intratumorally injected patients. The most obvious adverse side effect was mild and reversible bone marrow suppression. CONCLUSION: Radioimmunotherapy with (131)I-chTNT was well tolerated and can be used systemically or locally to treat refractory tumors of the lung.